Hudson Bay Capital Management
ARCT icon

Hudson Bay Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Hudson Bay Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,600
Closed -$195K – 1187
2025
Q3 		$195K Sell
10,600
-144,400
-93% -$2.32M ﹤0.01% 1028
2025
Q2 		$2.02M Buy
155,000
+100
+0.1% +$1.18K 0.01% 796
2025
Q1 		$1.64M Buy
154,900
+90,900
+142% +$1.44M 0.01% 856
2024
Q4 		$1.09M Buy
64,000
+20,000
+45% +$377K ﹤0.01% 733
2024
Q3 		$1.02M Buy
+44,000
New +$941K ﹤0.01% 670

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Hudson Bay Capital Management's ARCT Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 10,600 shares — an estimated $195K sold.

Hudson Bay Capital Management first reported a position in ARCT in Q3 2024 and held it in 5 quarters. The position peaked at $2.02M in Q2 2025. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Hudson Bay Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 10,600 Arcturus Therapeutics shares in Q4 2025, an estimated $195K.
  • Hudson Bay Capital Management first reported a position in Arcturus Therapeutics in Q3 2024 and held it in 5 quarters.
  • Hudson Bay Capital Management's Arcturus Therapeutics position peaked at $2.02M in Q2 2025.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.